• Completed

Phase II HOVON 143 Study: Ixazomib, Dara and Low Dose Dex in Intermediate-Fit Patients NDMM

Updated: Sep 22

Phase II HOVON 143 Study

Trial Update 63rd ASH Annual Meeting

HOVON 143


80 Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Phase 2 and 3 Trials in Myeloma

Hematology Disease Topics & Pathways:

Biological, Clinical Trials, Non-Biological, Elderly, Plasma Cell Disorders, Clinical Research, Diseases, Immunotherapy, Therapies, Adverse Events, Lymphoid Malignancies, Study Population

Saturday, December 11, 2021: 9:45 AM


Learn more

 

Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study

Volume 39, Issue 25, 2021

Abstract


Learn more

 

HOVON HO143 MM

https://hovon.nl/en

https://hovon.nl/en/trials/ho143


Title: Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and frail newly diagnosed multiple myeloma patients; an open-label phase II trial.


Primary objective:

To determine the efficacy, defined as overall response rate (ORR), of 9 cycles of ixazomib, daratumumab and low dose dexamethasone. Overall response will be defined as (stringent) complete response ((s)CR), very good partial (VGPR) response and partial response (PR)


 

HOVON 143 MM

Title

Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and frail newly diagnosed multiple myeloma patients; an open-label phase II trial

https://www.trialregister.nl/trial/6142


Posts Archive